Publications
Detailed Information
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Van Cutsem, Eric | - |
dc.contributor.author | Amonkar, Mayur | - |
dc.contributor.author | Fuchs, Charles S. | - |
dc.contributor.author | Alsina, Maria | - |
dc.contributor.author | Ozguroglu, Mustafa | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Chung, Hyun Cheol | - |
dc.contributor.author | Muro, Kei | - |
dc.contributor.author | Goekkurt, Eray | - |
dc.contributor.author | Benson, Al B., III | - |
dc.contributor.author | Sun, Weijing | - |
dc.contributor.author | Wainberg, Zev A. | - |
dc.contributor.author | Norquist, Josephine M. | - |
dc.contributor.author | Chen, Xinqun | - |
dc.contributor.author | Shih, Chie-Schin | - |
dc.contributor.author | Shitara, Kohei | - |
dc.date.accessioned | 2022-04-18T09:24:28Z | - |
dc.date.available | 2022-04-18T09:24:28Z | - |
dc.date.created | 2021-08-26 | - |
dc.date.created | 2021-08-26 | - |
dc.date.issued | 2021-11 | - |
dc.identifier.citation | Gastric Cancer, Vol.24 No.6, pp.1330-1340 | - |
dc.identifier.issn | 1436-3291 | - |
dc.identifier.other | 140614 | - |
dc.identifier.uri | https://hdl.handle.net/10371/178105 | - |
dc.description.abstract | Background In the primary analysis population (i.e., PD-L1 combined positive score [CPS] >= 1) of the phase 3 KEYNOTE-061 study (NCT02370498), pembrolizumab did not significantly prolong overall survival or progression-free survival. Pembrolizumab had a favorable safety profile in the all-patient population. We present results of prespecified health-related quality of life (HRQoL) analyses. Methods HRQoL was measured using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), EORTC QLQ gastric cancer questionnaire (QLQ-STO22), and EuroQol 5-dimension, 3-level questionnaire (EQ-5D-3L). Data were analyzed from patients who received >= 1 dose of study treatment and who completed >= 1 HRQoL assessment. Key analyses included baseline to week 12 least-squares mean (LSM) change in global health status (GHS)/QoL, functional/symptom subscales, and time to deterioration (TTD; >= 10-point decrease from baseline) for specific subscales. Results The HRQoL population included 371 patients (pembrolizumab, n = 188; paclitaxel, n = 183). Compliance and completion rates for all 3 questionnaires were similar in both groups at baseline and week 12. There was no difference in LSM change between groups (- 3.54; 95% CI - 8.92 to 1.84) in GHS/QoL at week 12. LSM change from baseline to week 12 for most QLQ-C30, QLQ-STO22, and EQ-5D-3L subscales indicated some worsening of QoL in both groups. TTD for GHS/QoL, nausea/vomiting, and appetite loss subscales in QLQ-C30 and the pain subscales in QLQ-STO22 were similar between treatment groups. Conclusions In this population with advanced gastric and GEJ cancer receiving second-line treatment, HRQoL was similar in patients receiving pembrolizumab and those receiving paclitaxel. | - |
dc.language | 영어 | - |
dc.publisher | Springer Verlag | - |
dc.title | Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1007/s10120-021-01200-w | - |
dc.citation.journaltitle | Gastric Cancer | - |
dc.identifier.wosid | 000682637100003 | - |
dc.identifier.scopusid | 2-s2.0-85112032966 | - |
dc.citation.endpage | 1340 | - |
dc.citation.number | 6 | - |
dc.citation.startpage | 1330 | - |
dc.citation.volume | 24 | - |
dc.identifier.sci | 000682637100003 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | EUROPEAN-ORGANIZATION | - |
dc.subject.keywordPlus | QUESTIONNAIRE | - |
dc.subject.keywordPlus | QLQ-C30 | - |
dc.subject.keywordPlus | MODULE | - |
dc.subject.keywordAuthor | Pembrolizumab | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | HRQoL | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.